Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...
Regeneron price target lowered to $1,045 from $1,059 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
RBC cuts Regeneron stock price target to $1,045, keeps Outperform
RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...
pharmaphorum23h
Regeneron gene therapy restores hearing in deaf child
Regeneron’s gene therapy for otoferlin-related ... The result comes from a phase 1/2 study of the company’s experimental adeno-associated virus (AAV) gene therapy DB-OTO and was seen in ...